Castle Biosciences Publishes Study Validating TissueCypher Test's Risk Stratification Capabilities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy CSTL?
Source: Newsfilter
- Risk Identification Capability: The newly published systematic review and meta-analysis demonstrate that the TissueCypher test can increase the identification rate of high-risk patients by 6.7 times, significantly outperforming traditional pathology methods, thereby enabling more effective personalized management by physicians.
- Clinical Validation: The study consolidates data from six studies, confirming TissueCypher's consistency and reproducibility in identifying high-risk patients, which enhances its clinical value as a risk stratification tool.
- Progression Rate Analysis: High-risk patients exhibit an annual progression rate of 5.6%, significantly higher than the 1.7% rate for low-risk patients, providing strong evidence for clinical intervention and helping physicians formulate more effective treatment plans.
- Personalized Care: By accurately identifying truly high-risk patients, TissueCypher not only boosts confidence in early intervention but also reduces unnecessary procedures for low-risk patients, optimizing the allocation of healthcare resources.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.900
Low
41.00
Averages
47.20
High
52.00
Current: 31.900
Low
41.00
Averages
47.20
High
52.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Castle Biosciences Expects 2025 Revenue to Exceed $340 Million
- Significant Revenue Growth: Castle Biosciences anticipates total revenue for 2025 to exceed $340 million, surpassing the previously guided range of $327-335 million, reflecting strong performance in its innovative test portfolio and bolstering confidence in future growth.
- Surge in Core Test Reports: Total test reports for core revenue drivers increased by 37% in 2025 compared to 2024, with DecisionDx-Melanoma reports reaching 39,083 and TissueCypher reports at 39,014, indicating a robust recovery in market demand.
- Successful New Test Launch: The limited access launch of AdvanceAD-Tx in November 2025 saw over 50% of 150 clinician offices placing orders within the first five weeks, demonstrating rapid market acceptance and further expanding the company's total addressable market.
- Strong Financial Position: Year-end 2025 cash and cash equivalents are expected to be approximately $300 million, alongside $184 million in marketable investment securities, showcasing a solid financial foundation that provides ample funding for future expansion and innovation.
See More
AstraZeneca Secures FDA Approval for Enhertu in First-Line Breast Cancer, Triggers $150M Milestone Payment
- FDA Approval: AstraZeneca and its partner Daiichi Sankyo's antibody-drug conjugate Enhertu has received FDA approval for first-line treatment of unresectable or metastatic HER2-positive breast cancer, marking a significant milestone in the U.S. market.
- Clinical Trial Results: The DESTINY-Breast09 study demonstrated that the Enhertu-Perjeta combination achieved a median progression-free survival of 40.7 months, a 51.5% improvement over the 26.9 months seen with the standard taxane chemotherapy, highlighting its superior efficacy.
- Financial Impact: This approval triggers a $150 million milestone payment from AstraZeneca to Daiichi Sankyo, further solidifying their global partnership and providing a new revenue growth avenue for AstraZeneca.
- Market Performance: Over the past year, AstraZeneca's stock has surged by 36.3%, significantly outperforming the industry average growth of 12.1%, reflecting strong market confidence in its newly approved drug and future growth potential.
See More
Novo Nordisk Submits NDA for Advanced Obesity Treatment CagriSema
Novo Nordisk's New Drug Application: Novo Nordisk has submitted an NDA to the FDA for CagriSema, a once-weekly injection aimed at reducing body weight in adults with obesity or overweight, expected to be reviewed in 2026.
Clinical Study Results: CagriSema demonstrated significant weight loss in two phase III studies, with patients achieving an average weight loss of 22.7% and 15.7% compared to placebo, and a favorable safety profile.
Market Challenges: Despite positive clinical results, Novo Nordisk's stock has declined due to pricing pressures and competition from Eli Lilly's obesity and diabetes drugs, which have rapidly gained market share.
Future Developments: Novo Nordisk is developing additional obesity treatments and expanding its semaglutide franchise, while also pursuing partnerships for new obesity and diabetes therapies.
See More
Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
- Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which will ultimately improve overall company performance.
- Grant Details: These RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service through each vesting date.
- Compliance Assurance: The grant complies with Nasdaq Listing Rule 5635(c)(4), which not only ensures the company's adherence to regulations in attracting and retaining key talent but also boosts investor confidence in corporate governance practices.
- Company Vision: Castle Biosciences focuses on improving health through innovative testing, dedicated to providing personalized solutions for dermatologic and gastroenterological diseases, aiming to enhance patient management and treatment outcomes through rigorous science and advanced molecular testing.
See More
Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
- Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which is expected to improve overall company performance.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent while enhancing investor confidence through compliance and transparency.
- Company Vision: Castle Biosciences focuses on improving health through innovative testing, particularly in dermatologic and gastroenterological diseases, and the RSU grants will further drive the company's strategic goals in personalized healthcare solutions.
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Castle Biosciences Expects 2025 Revenue to Exceed $340 Million
- Significant Revenue Growth: Castle Biosciences anticipates total revenue for 2025 to exceed $340 million, surpassing the previously guided range of $327-335 million, reflecting strong performance in its innovative test portfolio and bolstering confidence in future growth.
- Surge in Core Test Reports: Total test reports for core revenue drivers increased by 37% in 2025 compared to 2024, with DecisionDx-Melanoma reports reaching 39,083 and TissueCypher reports at 39,014, indicating a robust recovery in market demand.
- Successful New Test Launch: The limited access launch of AdvanceAD-Tx in November 2025 saw over 50% of 150 clinician offices placing orders within the first five weeks, demonstrating rapid market acceptance and further expanding the company's total addressable market.
- Strong Financial Position: Year-end 2025 cash and cash equivalents are expected to be approximately $300 million, alongside $184 million in marketable investment securities, showcasing a solid financial foundation that provides ample funding for future expansion and innovation.
See More
AstraZeneca Secures FDA Approval for Enhertu in First-Line Breast Cancer, Triggers $150M Milestone Payment
- FDA Approval: AstraZeneca and its partner Daiichi Sankyo's antibody-drug conjugate Enhertu has received FDA approval for first-line treatment of unresectable or metastatic HER2-positive breast cancer, marking a significant milestone in the U.S. market.
- Clinical Trial Results: The DESTINY-Breast09 study demonstrated that the Enhertu-Perjeta combination achieved a median progression-free survival of 40.7 months, a 51.5% improvement over the 26.9 months seen with the standard taxane chemotherapy, highlighting its superior efficacy.
- Financial Impact: This approval triggers a $150 million milestone payment from AstraZeneca to Daiichi Sankyo, further solidifying their global partnership and providing a new revenue growth avenue for AstraZeneca.
- Market Performance: Over the past year, AstraZeneca's stock has surged by 36.3%, significantly outperforming the industry average growth of 12.1%, reflecting strong market confidence in its newly approved drug and future growth potential.
See More
Novo Nordisk Submits NDA for Advanced Obesity Treatment CagriSema
Novo Nordisk's New Drug Application: Novo Nordisk has submitted an NDA to the FDA for CagriSema, a once-weekly injection aimed at reducing body weight in adults with obesity or overweight, expected to be reviewed in 2026.
Clinical Study Results: CagriSema demonstrated significant weight loss in two phase III studies, with patients achieving an average weight loss of 22.7% and 15.7% compared to placebo, and a favorable safety profile.
Market Challenges: Despite positive clinical results, Novo Nordisk's stock has declined due to pricing pressures and competition from Eli Lilly's obesity and diabetes drugs, which have rapidly gained market share.
Future Developments: Novo Nordisk is developing additional obesity treatments and expanding its semaglutide franchise, while also pursuing partnerships for new obesity and diabetes therapies.
See More
Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
- Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which will ultimately improve overall company performance.
- Grant Details: These RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service through each vesting date.
- Compliance Assurance: The grant complies with Nasdaq Listing Rule 5635(c)(4), which not only ensures the company's adherence to regulations in attracting and retaining key talent but also boosts investor confidence in corporate governance practices.
- Company Vision: Castle Biosciences focuses on improving health through innovative testing, dedicated to providing personalized solutions for dermatologic and gastroenterological diseases, aiming to enhance patient management and treatment outcomes through rigorous science and advanced molecular testing.
See More
Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
- Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which is expected to improve overall company performance.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent while enhancing investor confidence through compliance and transparency.
- Company Vision: Castle Biosciences focuses on improving health through innovative testing, particularly in dermatologic and gastroenterological diseases, and the RSU grants will further drive the company's strategic goals in personalized healthcare solutions.
See More
